Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas

Stopped No patient enrolled as new similar study will be in system within 3 months

Conditions

• Soft Tissue Sarcomas

Interventions

• BIOLOGICAL: Nivolumab
• DRUG: Pazopanib

Sponsor

NYU Langone Health

Collaborators

• [object Object]